Response to Comments: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

The provided document is an administrative response to comments for MolDX LCD L39594 regarding molecular biomarker testing for risk stratification of cutaneous squamous cell carcinoma and contains only the comment, notice, and effective dates. No clinical coverage indications, limitations, documentation requirements, or frequency limits are included in the text supplied. Review of the full LCD L39594 is required to extract actionable coverage criteria.

"This document is a response to public comments for MolDX LCD L39594 (Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma); it records the comment period (06/08/..."

Sign up to see full coverage criteria, indications, and limitations.